{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:13:56Z","timestamp":1785294836621,"version":"3.55.0"},"reference-count":211,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1157\/13088772","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T13:33:21Z","timestamp":1149600801000},"page":"697-706","source":"Crossref","is-referenced-by-count":5,"title":["Papel del polimorfismo gen\u00e9tico CYP2C19 en los efectos adversos a f\u00e1rmacos y en el riesgo para diversas enfermedades"],"prefix":"10.1016","volume":"126","author":[{"given":"Hortensia","family":"Alonso-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix J.","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Garc\u00eda-Ag\u00fandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1157\/13088772_bib1","series-title":"The acetylator genes and drug response","author":"Weber","year":"1987"},{"key":"10.1157\/13088772_bib2","series-title":"Molecular pathology of the nervous system","first-page":"35","article-title":"Pharmacogenetics and neurological disorders","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1993"},{"key":"10.1157\/13088772_bib3","first-page":"119","article-title":"Phenotype or genotype?","volume":"31","author":"Jackson","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib4","first-page":"401","article-title":"Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism","volume":"29","author":"Wong","year":"2000","journal-title":"Ann Acad Med Singapore"},{"key":"10.1157\/13088772_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1389200043335621","article-title":"Cytochrome P450 gene polymorphism and cancer","volume":"5","author":"Ag\u00fandez","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1157\/13088772_bib6","first-page":"852","article-title":"Polymorphic drug metabolism","volume":"8","author":"Relling","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1157\/13088772_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0404.1994.tb01643.x","article-title":"Acetylator polymorphism in multiple sclerosis","volume":"89","author":"Ladero","year":"1994","journal-title":"Acta Neurol Scand"},{"key":"10.1157\/13088772_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0404.1995.tb00481.x","article-title":"Frequency of CYP2D6 allelic variants in multiple sclerosis","volume":"92","author":"Ag\u00fandez","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1157\/13088772_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000113168","article-title":"CYP2D6 polymorphism is not associated with essential tremor","volume":"38","author":"Ag\u00fandez","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1157\/13088772_bib10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1212\/WNL.54.5.1195","article-title":"Polymorphism of NACP-Repl in Parkinson\u2019s disease: an etiologic link with essential tremor?","volume":"54","author":"Tan","year":"2000","journal-title":"Neurology"},{"key":"10.1157\/13088772_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/mds.10421","article-title":"Essential tremor is not associated with alpha-synuclein gene haplotypes","volume":"18","author":"Pigullo","year":"2003","journal-title":"Mov Disord"},{"key":"10.1157\/13088772_bib12","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/mds.20254","article-title":"Association of the C677T and A1298C polymorphism of methylentetrahydrofolate reductase gene in patients with essential tremor in Turkey","volume":"19","author":"Saczi","year":"2004","journal-title":"Mov Disord"},{"key":"10.1157\/13088772_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0278-6915(02)00210-7","article-title":"Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors","volume":"41","author":"Dorne","year":"2003","journal-title":"Food Chem Toxicol"},{"key":"10.1157\/13088772_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1749-6632.2000.tb06685.x","article-title":"Mimicking gene defects to treat drug dependence","volume":"909","author":"Sellers","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1157\/13088772_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1157\/13088772_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00008571-200212000-00004","article-title":"Identification and functional characterization of new potentially defective alleles of human CYP2C19","volume":"12","author":"Blaisdell","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0009-9236(95)90229-5","article-title":"The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study","volume":"57","author":"Balian","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-004-0833-1","article-title":"The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians","volume":"61","author":"Rosemary","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2125.1996.tb00179.x","article-title":"Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism","volume":"41","author":"Somogyi","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib21","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"De Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1157\/13088772_bib22","first-page":"594","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"De Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1157\/13088772_bib23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/clinchem\/45.12.2273","article-title":"Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4","volume":"45","author":"Garc\u00eda-Barcel\u00f3","year":"1999","journal-title":"Clin Chem"},{"key":"10.1157\/13088772_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00008571-199804000-00006","article-title":"An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians","volume":"8","author":"Ibeanu","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/004982598239506","article-title":"Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian","volume":"28","author":"Inoue","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1157\/13088772_bib26","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0006-2952(98)00022-7","article-title":"Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population","volume":"55","author":"Kubota","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1157\/13088772_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.1990.tb03653.x","article-title":"Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism","volume":"29","author":"Guttendorf","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00008571-199504000-00002","article-title":"The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos","volume":"5","author":"Evans","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0009-9236(95)90053-5","article-title":"Genetic analysis of the S-mephenytoin polymorphism in a Chinese population","volume":"58","author":"De Morais","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0024-3205(96)00507-3","article-title":"Genotype analysis of the CYP2C19 gene in the Japanese population","volume":"59","author":"Tsuneoka","year":"1996","journal-title":"Life Sci"},{"key":"10.1157\/13088772_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0773.1996.tb01379.x","article-title":"Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population","volume":"78","author":"Marandi","year":"1996","journal-title":"Pharmacol Toxicol"},{"key":"10.1157\/13088772_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00008571-199608000-00006","article-title":"CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population","volume":"6","author":"Jurima-Romet","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00008571-199610000-00008","article-title":"Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population","volume":"6","author":"Roh","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2125.1996.00500.x","article-title":"Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population","volume":"42","author":"Basci","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00008571-199612000-00005","article-title":"S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians","volume":"6","author":"Persson","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00008571-199702000-00008","article-title":"Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations","volume":"7","author":"Goldstein","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib37","first-page":"604","article-title":"Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele","volume":"281","author":"Xiao","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13088772_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s002280050372","article-title":"Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia","volume":"53","author":"Marandi","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0009-9236(98)90037-6","article-title":"Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects","volume":"63","author":"Lamba","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-199806000-00001","article-title":"Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population","volume":"20","author":"Kimura","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s002280050488","article-title":"Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in SouthPacific Polynesian populations","volume":"54","author":"Wanwimolruk","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0009-9236(98)90070-4","article-title":"Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype","volume":"64","author":"Herrlin","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/cp.1999.v66.100072001","article-title":"Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population","volume":"66","author":"Aynacioglu","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2125.1999.00009.x","article-title":"Genetic polymorphism of (S)-mephenytoin 4\u2019-hydroxylation in populations of African descent","volume":"48","author":"Xie","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00008571-199910000-00001","article-title":"Allelic, genotypic and phenotypic distributions of S-mephenytoin 4\u2019-hydroxylase( CYP2C19) in healthy Caucasian populations of European descent throughout the world","volume":"9","author":"Xie","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1067\/mcp.2000.109365","article-title":"CYP2C19 genetic mutations in North Indians","volume":"68","author":"Lamba","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib47","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00007691-200010000-00002","article-title":"Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping. Israeli ethnic groups","volume":"22","author":"Britzi","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/bmc.19","article-title":"Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S\/R enantiomeric ratio in urine measured by chiral GC","volume":"15","author":"Yao","year":"2001","journal-title":"Biomed Chromatogr"},{"key":"10.1157\/13088772_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00008571-200102000-00008","article-title":"Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from wester Australia","volume":"11","author":"Griese","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002280100282","article-title":"Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients","volume":"57","author":"Dandara","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib51","first-page":"52","article-title":"Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations","volume":"19","author":"Zhang","year":"2002","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"10.1157\/13088772_bib52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00008571-200204000-00006","article-title":"Analysis of the CYP2C19 polymorphism in a North-eastern Thai population","volume":"12","author":"Tassaneeyakul","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00228-002-0425-x","article-title":"CYP2C19 genotype and S-mephenytoin 4\u2019-hydroxylation phenotype in a Chinese Dai population","volume":"58","author":"He","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2125.2002.01604.x","article-title":"Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population","volume":"53","author":"Hamdy","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00228-002-0509-7","article-title":"Polymorphic oxidative metabolism of proguanil in a Nigerian population","volume":"58","author":"Bolaji","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0940-2993(04)70125-6","article-title":"Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions","volume":"54","author":"Hippius","year":"2003","journal-title":"Exp Toxicol Pathol"},{"key":"10.1157\/13088772_bib57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","article-title":"Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population","volume":"59","author":"Gaikovitch","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2125.2003.01883.x","article-title":"Allele and genotype frequency of CYP2C19 in a Tamilian population","volume":"56","author":"Adithan","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib59","first-page":"425","article-title":"Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population","volume":"44","author":"Bozina","year":"2003","journal-title":"Croat Med J"},{"key":"10.1157\/13088772_bib60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/DMR-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metab Rev"},{"key":"10.1157\/13088772_bib61","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/0091270003258170","article-title":"CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans","volume":"43","author":"Gonz\u00e1lez","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1157\/13088772_bib62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.2003.01937.x","article-title":"Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian population","volume":"56","author":"Allabi","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0091270004265702","article-title":"Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability","volume":"44","author":"Yin","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1157\/13088772_bib64","first-page":"161","article-title":"Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population","volume":"39","author":"Fu","year":"2004","journal-title":"Yao Xue Xue Bao"},{"key":"10.1157\/13088772_bib65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.phrs.2004.01.004","article-title":"Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population","volume":"50","author":"Scordo","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1157\/13088772_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2125.2004.02144.x","article-title":"Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects","volume":"58","author":"Pang","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1472-8206.2004.00307.x","article-title":"CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population","volume":"19","author":"Jose","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1157\/13088772_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00228-004-0890-5","article-title":"Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study","volume":"61","author":"Bravo-Villalta","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib69","unstructured":"Alonso-Navarro H. Polimorfismo CYP2C19 en el riesgo para el desarrollo de temblor esencial. Tesis Doctoral. Universidad de Salamanca, Julio 2005."},{"key":"10.1157\/13088772_bib70","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clpt.2004.08.021","article-title":"Bioequivalence revisited: influence of age and sex on CYP enzymes","volume":"76","author":"Bebia","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0773.2004.pto950102.x","article-title":"CYP2C19 polymorphism and proton pump inhibitors","volume":"95","author":"Klotz","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1157\/13088772_bib72","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/00498250400026472","article-title":"Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro","volume":"35","author":"Liu","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1157\/13088772_bib74","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1995.tb04488.x","article-title":"Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19","volume":"39","author":"Chang","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib75","first-page":"1081","article-title":"Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes","volume":"24","author":"Karam","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s002280050590","article-title":"CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin","volume":"55","author":"Zhou","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib77","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0009-9236(99)70075-5","article-title":"CYP2C19 genotype status and effect of omeprazole on intragastric Ph in humans","volume":"65","author":"Furuta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0009-9236(99)70034-2","article-title":"Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans","volume":"66","author":"Furuta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib79","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0009-9236(99)70017-2","article-title":"CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori","volume":"66","author":"Tanigawara","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 11","key":"10.1157\/13088772_bib80","first-page":"80","article-title":"Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers","volume":"34","author":"Aoyama","year":"1999","journal-title":"J Gastroenterol"},{"key":"10.1157\/13088772_bib81","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/gast.2000.16515","article-title":"Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism","volume":"119","author":"Sagar","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1157\/13088772_bib82","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1365-2036.2000.00835.x","article-title":"Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders","volume":"14","author":"Sagar","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1067\/mcp.2001.113959","article-title":"Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin","volume":"69","author":"Furuta","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib84","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/mcp.2001.114231","article-title":"Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19","volume":"69","author":"Yu","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1023\/A:1011025125163","article-title":"CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability","volume":"18","author":"Kita","year":"2001","journal-title":"Pharm Res"},{"key":"10.1157\/13088772_bib86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s002280100334","article-title":"Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians","volume":"57","author":"Lamba","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib87","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1440-1746.2002.02790.x","article-title":"Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype","volume":"17","author":"Inaba","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1157\/13088772_bib88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1067\/mcp.2002.126176","article-title":"Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19","volume":"72","author":"Kim","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib89","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1572-0241.2003.07427.x","article-title":"The clinical role of cytochrome p450 genotypes in Helicobacter pylori management","volume":"98","author":"Sapone","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13088772_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-200106000-00009","article-title":"Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin","volume":"11","author":"Furuta","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib91","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2036.2001.00980.x","article-title":"Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes","volume":"15","author":"Horai","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib92","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s002280100342","article-title":"Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism","volume":"57","author":"Ieiri","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib93","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1440-1746.2003.03126.x","article-title":"Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?","volume":"18","author":"Inamori","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1157\/13088772_bib94","first-page":"777","article-title":"The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism","volume":"42","author":"Wang","year":"2003","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1157\/13088772_bib95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.clpt.2004.06.008","article-title":"Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status","volume":"76","author":"Sugimoto","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib96","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s002280050307","article-title":"Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects","volume":"52","author":"Katsuki","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib97","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0009-9236(97)90137-5","article-title":"Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4\u2019-hydroxylation phenotype status","volume":"61","author":"Sohn","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib98","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1067\/mcp.2000.106826","article-title":"Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient","volume":"67","author":"Furuta","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib99","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1046\/j.1365-2036.2000.00840.x","article-title":"CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole","volume":"14","author":"Adachi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1067\/mcp.2002.127637","article-title":"Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole","volume":"72","author":"Furuta","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib101","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0731-7085(02)00524-1","article-title":"Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype","volume":"30","author":"Kanazawa","year":"2003","journal-title":"J Pharm Biomed Anal"},{"key":"10.1157\/13088772_bib102","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.2003.01539.x","article-title":"(Study Group of GERD). The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism","volume":"17","author":"Kawamura","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib103","first-page":"986","article-title":"Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes","volume":"25","author":"Hu","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"10.1157\/13088772_bib104","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.clpt.2004.05.002","article-title":"CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole- based quadruple therapy for eradication of Helicobacter pylori","volume":"76","author":"Schwab","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00228-004-0809-1","article-title":"Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes","volume":"60","author":"Miura","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib106","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2036.2005.02353.x","article-title":"Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19","volume":"21","author":"Okudaira","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib107","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2125.2004.02329.x","article-title":"Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes","volume":"59","author":"Saito","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib108","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2036.2005.02281.x","article-title":"Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism","volume":"21","author":"Sheu","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1742-7843.2004.950302.x","article-title":"Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes","volume":"95","author":"Roh","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1157\/13088772_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2036.2003.01659.x","article-title":"High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection","volume":"18","author":"Isomoto","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib111","first-page":"468","article-title":"Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype","volume":"42","author":"Lee","year":"2003","journal-title":"Korean J Gastroenterol"},{"key":"10.1157\/13088772_bib112","first-page":"13","article-title":"Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese","volume":"43","author":"He","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1157\/13088772_bib113","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1440-1746.2001.02526.x","article-title":"A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism","volume":"16","author":"Miyoshi","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1157\/13088772_bib114","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1046\/j.1365-2036.2001.01063.x","article-title":"Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism","volume":"15","author":"Hokari","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s005350170029","article-title":"Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations","volume":"36","author":"Yamada","year":"2001","journal-title":"J Gastroenterol"},{"key":"10.1157\/13088772_bib116","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1590-8658(01)80043-8","article-title":"Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan","volume":"33","author":"Dojo","year":"2001","journal-title":"Dig Liver Dis"},{"key":"10.1157\/13088772_bib117","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1023\/A:1012371702918","article-title":"Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis","volume":"46","author":"Miwa","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1157\/13088772_bib118","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/147323000203000408","article-title":"Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers","volume":"30","author":"Wada","year":"2002","journal-title":"J Int Med Res"},{"key":"10.1157\/13088772_bib119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00042737-200301000-00006","article-title":"Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan","volume":"15","author":"Miki","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13088772_bib120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1745-7254.2005.00047.x","article-title":"Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects","volume":"26","author":"Hu","year":"2005","journal-title":"Acta Pharmacol Sin"},{"key":"10.1157\/13088772_bib121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-200201000-00010","article-title":"Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism","volume":"12","author":"Lutz","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib122","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1177\/0091270003259389","article-title":"Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer","volume":"43","author":"Lehmann","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1157\/13088772_bib123","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/phgs.5.2.181.27483","article-title":"Pharmacogenomics of proton pump inhibitors","volume":"5","author":"Furuta","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1157\/13088772_bib124","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1211\/0022357043914","article-title":"Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations","volume":"56","author":"Itagaki","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1157\/13088772_bib125","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1345\/aph.1D366","article-title":"Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism","volume":"38","author":"Takahashi","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1157\/13088772_bib126","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/mcp.2001.114231","article-title":"Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19","volume":"69","author":"Yu","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib127","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2036.1999.00490.x","article-title":"Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment","volume":"13","author":"Sagar","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13088772_bib128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0009-9236(99)90082-6","article-title":"Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers","volume":"65","author":"Ko","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib129","first-page":"2403","article-title":"Interleukin-1beta genetic polymorphism influences the effect of cytochrome P2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection","volume":"98","author":"Take","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13088772_bib130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1542-3565(03)00288-X","article-title":"Polymorphism of interleukin-1 beta affects the eradication rates of Helicobacter pylori by triple therapy","volume":"2","author":"Furuta","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1157\/13088772_bib131","first-page":"455","article-title":"Interluekin-1 beta genetic polymorphism influences the impact of cytochrome P2C19 genotype on the cure rate of H. pylori eradication therapy","volume":"62","author":"Mizuno","year":"2004","journal-title":"Nippon Rinsho"},{"key":"10.1157\/13088772_bib132","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","article-title":"CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages","volume":"104","author":"Kirchheiner","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1157\/13088772_bib133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-002-0445-6","article-title":"The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects","volume":"58","author":"Jiang","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib134","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1440-1819.1997.tb02593.x","article-title":"Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy","volume":"51","author":"Morinobu","year":"1997","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1157\/13088772_bib135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.jcp.0000088909.24613.92","article-title":"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics","volume":"23","author":"Kirchheiner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1157\/13088772_bib136","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00008571-200210000-00010","article-title":"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers","volume":"12","author":"Kirchheiner","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib137","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.0306-5251.2001.01402.x","article-title":"Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects","volume":"52","author":"Liu","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib138","first-page":"85","article-title":"Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes","volume":"22","author":"Liu","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1157\/13088772_bib139","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1365-2125.1999.00023.x","article-title":"Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes","volume":"48","author":"Xu","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mcp.2001.116513","article-title":"Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19","volume":"70","author":"Wang","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib141","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/dmd.31.10.1255","article-title":"Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19","volume":"31","author":"Yu","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib142","first-page":"143","article-title":"Metabolism of the newest antidepressants: comparisons with related predecessors","volume":"7","author":"Caccia","year":"2004","journal-title":"Idrugs"},{"key":"10.1157\/13088772_bib143","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002280050737","article-title":"The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population","volume":"56","author":"Fukuda","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/DMDI.2002.19.1.1","article-title":"Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype","volume":"19","author":"Jan","year":"2002","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1157\/13088772_bib145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s002280050261","article-title":"Relationship between fluvoxamine pharmacokinetics and CYP2D6\/CYP2C19 phenotype polymorphisms","volume":"52","author":"Spigset","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib146","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1373\/clinchem.2003.030825","article-title":"Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers","volume":"50","author":"Steimer","year":"2004","journal-title":"Clin Chem"},{"key":"10.1157\/13088772_bib147","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1373\/clinchem.2004.041327","article-title":"Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy","volume":"51","author":"Steimer","year":"2005","journal-title":"Clin Chem"},{"key":"10.1157\/13088772_bib148","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/cp.1999.v66.103379001","article-title":"Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects","volume":"66","author":"Qin","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib149","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1996.tb00010.x","article-title":"The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype","volume":"42","author":"Wan","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007691-200212000-00009","article-title":"Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam","volume":"24","author":"Contin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib151","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib152","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","article-title":"A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam","volume":"26","author":"Kosaki","year":"2004","journal-title":"Brain Dev"},{"key":"10.1157\/13088772_bib153","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00007691-200410000-00011","article-title":"Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity","volume":"26","author":"Fukasawa","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib154","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00008571-199610000-00002","article-title":"Formation of meprobamate from carisoprodol is catalysed by CYP2C19","volume":"6","author":"Dalen","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00008571-200307000-00003","article-title":"Association between blood carisoprodol: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1\/CYP2C19*2 subjects?","volume":"13","author":"Bramness","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib156","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/elps.200305512","article-title":"Assessment of the stereoselective metabolism of methaqualone in man by capillary electrophoresis","volume":"24","author":"Prost","year":"2003","journal-title":"Electrophoresis"},{"key":"10.1157\/13088772_bib157","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0090-9556(24)02975-1","article-title":"CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes","volume":"32","author":"Ram\u00edrez","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib158","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007691-200004000-00016","article-title":"Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication","volume":"22","author":"Ninomiya","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib159","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00007691-200102000-00014","article-title":"Phenytoin intoxication induced by fluvoxamine","volume":"23","author":"Mamiya","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.tpj.6500025","article-title":"The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels","volume":"1","author":"Kerb","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"10.1157\/13088772_bib161","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","article-title":"The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics","volume":"39","author":"Mamiya","year":"1998","journal-title":"Epilepsia"},{"key":"10.1157\/13088772_bib162","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1248\/bpb.19.1103","article-title":"Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy","volume":"19","author":"Hashimoto","year":"1996","journal-title":"Biol Pharm Bull"},{"key":"10.1157\/13088772_bib163","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0009-9236(97)90031-X","article-title":"Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy","volume":"62","author":"Odani","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib164","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00007691-200410000-00012","article-title":"Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9\/CYP2C19 polymorphisms","volume":"26","author":"Hung","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib165","first-page":"1686","article-title":"Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration","volume":"84","author":"Huang","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1157\/13088772_bib166","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2125.1997.00572.x","article-title":"Stereoselective 4\u2019-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese","volume":"43","author":"Ieiri","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib167","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0009-8981(01)00696-9","article-title":"CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase","volume":"313","author":"Zhou","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1157\/13088772_bib168","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0022-3565(24)37213-1","article-title":"A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin","volume":"284","author":"Ferguson","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13088772_bib169","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0022-3565(24)37748-1","article-title":"Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin","volume":"286","author":"Ibeanu","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13088772_bib170","first-page":"635","article-title":"A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin","volume":"290","author":"Ibeanu","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13088772_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2004.05.015","article-title":"Active- site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors","volume":"429","author":"Suzuki","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"10.1157\/13088772_bib172","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050703","article-title":"CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics","volume":"55","author":"Mamiya","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib173","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-200104000-00004","article-title":"P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism","volume":"23","author":"Hadama","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13088772_bib174","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.fpc.0000114764.78957.22","article-title":"Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of Rand S-mephobarbital in humans","volume":"14","author":"Kobayashi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00008571-199704000-00003","article-title":"Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and S-mephenytoin 4\u2019-hydroxylation activities in livers of Japanese and Caucasian populations","volume":"7","author":"Inoue","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00008571-200203000-00004","article-title":"Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers","volume":"12","author":"Kirchheiner","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib177","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00008571-200203000-00005","article-title":"Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans","volume":"12","author":"Shon","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib178","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.1990.tb03777.x","article-title":"In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence in vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme","volume":"30","author":"Helsby","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib179","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0009-9236(97)90030-8","article-title":"Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide","volume":"62","author":"Jeppesen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2125.1997.00596.x","article-title":"Association between CYP2C19 genotype and proguanil oxidative polymorphism","volume":"43","author":"Coller","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1157\/13088772_bib181","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.1999.00005.x","article-title":"Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms","volume":"48","author":"Coller","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib182","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1989.11","article-title":"Propranolol\u2019s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities","volume":"45","author":"Ward","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib183","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/cbt.318","article-title":"Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide","volume":"1","author":"Ando","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"10.1157\/13088772_bib184","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00008571-199706000-00006","article-title":"Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation","volume":"7","author":"Chang","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00228-003-0590-6","article-title":"Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes","volume":"59","author":"Griskevicius","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib186","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s002280100289","article-title":"CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline","volume":"57","author":"Laine","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib187","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2125.1996.00471.x","article-title":"Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans","volume":"42","author":"Bottiger","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib188","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0009-9236(98)90103-5","article-title":"Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes","volume":"63","author":"Takahashi","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib189","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1067\/mcp.2002.129321","article-title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance","volume":"72","author":"Scordo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1157\/13088772_bib190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s002280050629","article-title":"Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)","volume":"55","author":"Sandwall","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1157\/13088772_bib191","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2125.2000.00230.x","article-title":"CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system","volume":"50","author":"Ford","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1157\/13088772_bib192","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1124\/dmd.104.001743","article-title":"Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19","volume":"32","author":"Hirani","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib193","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1157\/13088772_bib194","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/0049825021000023996","article-title":"Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype- dependent","volume":"33","author":"He","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1157\/13088772_bib195","first-page":"1284","article-title":"Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status","volume":"29","author":"Kosuge","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1157\/13088772_bib196","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1248\/bpb.28.882","article-title":"Inhibitory effects of nicardipine to cytochrome P450 (CYP) in Human Liver Microsomes","volume":"28","author":"Nakamura","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1157\/13088772_bib197","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008571-199906000-00008","article-title":"Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer","volume":"9","author":"Wadelius","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib198","first-page":"3915","article-title":"Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk","volume":"56","author":"Brockmoller","year":"1996","journal-title":"Cancer Res"},{"key":"10.1157\/13088772_bib199","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0024-3205(00)00757-8","article-title":"Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma","volume":"67","author":"Chau","year":"2000","journal-title":"Life Sci"},{"key":"10.1157\/13088772_bib200","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3748\/wjg.v10.i13.463","article-title":"Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population","volume":"10","author":"Shi","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1157\/13088772_bib201","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/carcin\/23.11.1839","article-title":"A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer","volume":"23","author":"Sachse","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1157\/13088772_bib202","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00008571-200010000-00004","article-title":"Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia","volume":"10","author":"Roddam","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1157\/13088772_bib203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard.58.3.182","article-title":"CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus","volume":"58","author":"Kortunay","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13088772_bib204","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13088772_bib205","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1523-1747.2003.12124.x","article-title":"Allelic variants of drug metabolizing enzymes as risk factors in psoriasis","volume":"120","author":"Richter-Hintz","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1157\/13088772_bib206","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10776-003-0646-7","article-title":"Genetic analysis of steroid-induced osteonecrosis of the femoral head","volume":"8","author":"Asano","year":"2003","journal-title":"J Orthop Sci"},{"key":"10.1157\/13088772_bib207","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00002093-199809000-00013","article-title":"No association between familial Alzheimer disease and cytochrome P450 polymorphisms","volume":"12","author":"Yamada","year":"1998","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1157\/13088772_bib208","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/jnnp.74.8.1161","article-title":"Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis","volume":"74","author":"Bachus","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1157\/13088772_bib209","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2710.1999.00201.x","article-title":"Clinically significant pharmacokinetic drug interactions between antiepileptic drugs","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"10.1157\/13088772_bib210","series-title":"Farmacolog\u00eda humana","author":"Fl\u00f3rez","year":"2003"},{"key":"10.1157\/13088772_bib211","unstructured":"Cavazos JE. Post-stroke seizures and epilepsy in the elderly population. En: Profiles in seizure management: Pharmacy series. Continuing Medical Education (CME): Princeton Media Associates. Disponible en: http:\/\/www.princetoncme.com\/public\/2004-80-02\/report192.html"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775306720656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775306720656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:09:41Z","timestamp":1736402981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775306720656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":211,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0025775306720656"],"URL":"https:\/\/doi.org\/10.1157\/13088772","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}